Barclays PLC Initiates Coverage on Juno Therapeutics, Inc. (JUNO)
Barclays PLC began scope on offers of Juno Therapeutics, Inc. (NASDAQ:JUNO) in a report issued on Wednesday, September sixth, MarketBeat Ratings reports. The firm issued an overweight rating and a $55.00 value focus on the biopharmaceutical organization's stock.
JUNO has been the subject of a few different reports. Zacks Investment Research minimized Juno Therapeutics from a purchase rating to a hold rating in a cover Thursday, August third. Morgan Stanley expanded their value focus on Juno Therapeutics from $26.00 to $27.00 and gave the stock an equivalent weight rating in a give an account of Monday, August seventh. Vetr minimized Juno Therapeutics from a purchase rating to a hold rating and set a $28.85 target cost for the organization. in a provide details regarding Monday, June 26th. FBR and Co reissued a hold rating on offers of Juno Therapeutics in an investigate Thursday, May eighteenth. At long last, BidaskClub raised Juno Therapeutics from a hold rating to a purchase rating in a provide details regarding Tuesday, June twentieth. Three venture investigators have evaluated the stock with an offer rating, six have given a hold rating and nine have given a purchase rating to the organization. The organization has an accord rating of Hold and an agreement target cost of $34.88.
Get Juno Therapeutics Inc. alarms:
Enter Your Email Address
Submit
Offers of Juno Therapeutics (JUNO) exchanged up 2.36% amid exchanging on Wednesday, hitting $46.39. 2,472,657 offers of the organization exchanged hands. Juno Therapeutics has a 52 week low of $17.52 and a 52 week high of $47.00. The organization's market capitalization is $4.87 billion. The organization has a 50 day moving normal cost of $32.75 and a 200 day moving normal cost of $26.72.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly profit information on Thursday, August third. The biopharmaceutical organization detailed ($0.96) income per share for the quarter, missing the Thomson Reuters' accord gauge of ($0.72) by ($0.24). Juno Therapeutics had a negative net edge of 354.36% and a negative profit for value of 27.10%. The firm had income of $21.30 million amid the quarter, contrasted with expert appraisals of $15.59 million. Amid a similar period in the earlier year, the organization posted ($0.64) income per share. Juno Therapeutics' income was down 22.8% contrasted with a similar quarter a year ago. All things considered, examiners expect that Juno Therapeutics will post ($3.12) income per share for the present year.
Elsewhere in the world, significant investor Douglas K. Bratton sold 8,000,000 offers of Juno Therapeutics stock in an exchange dated Thursday, July thirteenth. The stock was sold at a normal cost of $27.00, for an aggregate estimation of $216,000,000.00. The exchange was revealed in a record documented with the SEC, which is accessible through this connection. Additionally, CFO Steve Harr sold 8,750 offers of Juno Therapeutics stock in an exchange dated Tuesday, June 27th. The offers were sold at a normal cost of $30.00, for an aggregate estimation of $262,500.00. Following the culmination of the exchange, the CFO now straightforwardly claims 736,189 offers in the organization, esteemed at $22,085,670. The divulgence for this deal can be found here. Insiders sold an aggregate of 8,078,369 offers of organization stock worth $218,620,477 in the course of the most recent ninety days. Corporate insiders claim 15.26% of the organization's stock.
Various institutional financial specialists have as of late added to or diminished their stakes in JUNO. The Manufacturers Life Insurance Company lifted its position in Juno Therapeutics by 7.2% amid the second quarter. The Manufacturers Life Insurance Company now possesses 3,405 offers of the biopharmaceutical organization's stock worth $102,000 in the wake of securing an extra 228 offers in the last quarter. Pacad Investment Ltd. procured another position in Juno Therapeutics amid the second quarter worth around $105,000. QS Investors LLC obtained another position in Juno Therapeutics amid the second quarter worth around $135,000. Awesome West Life Assurance Co. Can lifted its position in Juno Therapeutics by 80.5% amid the first quarter. Extraordinary West Life Assurance Co. Would now be able to claims 8,518 offers of the biopharmaceutical organization's stock worth $189,000 in the wake of procuring an extra 3,800 offers in the last quarter. At last, Nisa Investment Advisors LLC procured another position in Juno Therapeutics amid the first quarter worth roughly $200,000. 70.76% of the stock is as of now claimed by flexible investments and other institutional financial specialists.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical organization, which is centered around creating cell immunotherapies for the treatment of malignancy. The Company is creating cell-construct growth immunotherapies situated in light of its fanciful antigen receptor (CAR) and T cell receptor (TCR) advances to hereditarily design T cells to perceive and execute disease cells.
JUNO has been the subject of a few different reports. Zacks Investment Research minimized Juno Therapeutics from a purchase rating to a hold rating in a cover Thursday, August third. Morgan Stanley expanded their value focus on Juno Therapeutics from $26.00 to $27.00 and gave the stock an equivalent weight rating in a give an account of Monday, August seventh. Vetr minimized Juno Therapeutics from a purchase rating to a hold rating and set a $28.85 target cost for the organization. in a provide details regarding Monday, June 26th. FBR and Co reissued a hold rating on offers of Juno Therapeutics in an investigate Thursday, May eighteenth. At long last, BidaskClub raised Juno Therapeutics from a hold rating to a purchase rating in a provide details regarding Tuesday, June twentieth. Three venture investigators have evaluated the stock with an offer rating, six have given a hold rating and nine have given a purchase rating to the organization. The organization has an accord rating of Hold and an agreement target cost of $34.88.
Get Juno Therapeutics Inc. alarms:
Enter Your Email Address
Submit
Offers of Juno Therapeutics (JUNO) exchanged up 2.36% amid exchanging on Wednesday, hitting $46.39. 2,472,657 offers of the organization exchanged hands. Juno Therapeutics has a 52 week low of $17.52 and a 52 week high of $47.00. The organization's market capitalization is $4.87 billion. The organization has a 50 day moving normal cost of $32.75 and a 200 day moving normal cost of $26.72.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly profit information on Thursday, August third. The biopharmaceutical organization detailed ($0.96) income per share for the quarter, missing the Thomson Reuters' accord gauge of ($0.72) by ($0.24). Juno Therapeutics had a negative net edge of 354.36% and a negative profit for value of 27.10%. The firm had income of $21.30 million amid the quarter, contrasted with expert appraisals of $15.59 million. Amid a similar period in the earlier year, the organization posted ($0.64) income per share. Juno Therapeutics' income was down 22.8% contrasted with a similar quarter a year ago. All things considered, examiners expect that Juno Therapeutics will post ($3.12) income per share for the present year.
Elsewhere in the world, significant investor Douglas K. Bratton sold 8,000,000 offers of Juno Therapeutics stock in an exchange dated Thursday, July thirteenth. The stock was sold at a normal cost of $27.00, for an aggregate estimation of $216,000,000.00. The exchange was revealed in a record documented with the SEC, which is accessible through this connection. Additionally, CFO Steve Harr sold 8,750 offers of Juno Therapeutics stock in an exchange dated Tuesday, June 27th. The offers were sold at a normal cost of $30.00, for an aggregate estimation of $262,500.00. Following the culmination of the exchange, the CFO now straightforwardly claims 736,189 offers in the organization, esteemed at $22,085,670. The divulgence for this deal can be found here. Insiders sold an aggregate of 8,078,369 offers of organization stock worth $218,620,477 in the course of the most recent ninety days. Corporate insiders claim 15.26% of the organization's stock.
Various institutional financial specialists have as of late added to or diminished their stakes in JUNO. The Manufacturers Life Insurance Company lifted its position in Juno Therapeutics by 7.2% amid the second quarter. The Manufacturers Life Insurance Company now possesses 3,405 offers of the biopharmaceutical organization's stock worth $102,000 in the wake of securing an extra 228 offers in the last quarter. Pacad Investment Ltd. procured another position in Juno Therapeutics amid the second quarter worth around $105,000. QS Investors LLC obtained another position in Juno Therapeutics amid the second quarter worth around $135,000. Awesome West Life Assurance Co. Can lifted its position in Juno Therapeutics by 80.5% amid the first quarter. Extraordinary West Life Assurance Co. Would now be able to claims 8,518 offers of the biopharmaceutical organization's stock worth $189,000 in the wake of procuring an extra 3,800 offers in the last quarter. At last, Nisa Investment Advisors LLC procured another position in Juno Therapeutics amid the first quarter worth roughly $200,000. 70.76% of the stock is as of now claimed by flexible investments and other institutional financial specialists.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical organization, which is centered around creating cell immunotherapies for the treatment of malignancy. The Company is creating cell-construct growth immunotherapies situated in light of its fanciful antigen receptor (CAR) and T cell receptor (TCR) advances to hereditarily design T cells to perceive and execute disease cells.
Post a Comment